UCSD Asthma Study
The purpose of this over is to determine the effectiveness and safety of SYMBICORT® pMDI [a medication approved by the Food and Drug Management, (FDA)] in the African American population. SYMBICORT® pMDI (pressurized metered dose inhaler) combines two drugs, budesonide and formoterol. Budesonide is an inhaled steroid. It is habituated to in the treatment of asthma and provides overall control of the disease in the African American population.
Pulmicort inhaler - News
AstraZeneca settles US pulmicort respules patent litigation with Teva Alibaba News Channel
Alibaba Information ChannelAstraZeneca settles US pulmicort respules patent litigation with TevaAlibaba News Channel,nbsp;NEW YORKnbsp;- The agreement agreement will allow Teva to commence sales of budesonide inhalation suspension, under an exclusive approve from AstraZeneca beginning 15
|
|
MAP Pharmaceuticals, AstraZeneca partner on asthma drug Bizjournals.com MAP Pharmaceuticals, AstraZeneca companion on asthma drugBizjournals.com,nbsp;NCnbsp;- called Pulmicort Respules, and at a lower nominal quantity. MAP is developing its drug, an inhaled corticosteroid, as a potential treatment for pediatric |
|
AstraZeneca And MAP Pharmaceuticals Announce Worldwide Pharmaceutical Online (press release) AstraZeneca And MAP Pharmaceuticals Intimate WorldwidePharmaceutical Online (press release),nbsp;PAnbsp;- The company applies its proprietary inhalation technologies to reinforce the therapeutic benefits and commercial attractiveness of proven drugs while |